All In Biotech

Drug Trial Radar · NCT06541262

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Oct 30, 2024

Primary completion

Nov 1, 2030

Study completion Nov 1, 2035

Sponsor

Lead sponsor
Milton S. Hershey Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of silmitasertib in combination with chemotherapy * Test the safety and tolerability of silmitasertib in combination with chemotherapy in subjects with cancer * To determine the activity of study treatments chosen based on: * How each subject responds to the study treatment * How long a subject lives without their disease returning/progressing

Conditions

  • Neuroblastoma
  • Ewing Sarcoma
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Liposarcoma

Interventions

  • SilmitasertibDrug

    Capsules

  • IrinotecanDrug

    IV

  • TemozolomideDrug

    Oral or IV

  • VincristineDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 2 years plus 30 days
  2. Phase I- Number of Participants with Dose Limiting Toxicities to determine RP2DTime frame: 21 days
  3. Phase II- Determine the Overall Response Rate (ORR) of Participants using INRCTime frame: 2 years

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama/Children's of Alabama

    Birmingham, Alabama · Recruiting

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Rady Children's Hospital

    San Diego, California · Recruiting

  • Connecticut Children's Hospital

    Hartford, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • All Children's Hospital Johns Hopkins Medicine

    St. Petersburg, Florida · Recruiting

  • St. Joseph's Children's Hospital

    Tampa, Florida · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine

    Louisville, Kentucky · Recruiting

  • Children's Hospital of Michigan/Wayne State University

    Detroit, Michigan · Recruiting

  • Children's Mercy Hospitals and Clinics

    Kansas City, Missouri · Recruiting

  • Cardinal Glennon Children's Medical Center

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Penn State Milton S. Hershey Medical Center and Children's Hospital

    Hershey, Pennsylvania · Recruiting

  • Hasbro Children's Hospital

    Providence, Rhode Island · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Monroe Carrell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee · Recruiting

  • Children's Medical Center

    Dallas, Texas · Recruiting

  • Primary Children's Hospital

    Salt Lake City, Utah · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • UHC Sainte-Justine

    Montreal, Quebec, Canada · Recruiting

  • CIUSSS de l'Estrie-CHUS

    Sherbrooke, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.